阿替利珠单抗联合考比替尼治疗实体瘤的Ib期研究
这项I/Ib期研究在剂量递增阶段和多个适应症特异性剂量扩展队列中,治疗了未接受过PD-L1/PD-1治疗的实体瘤患者,考比替尼多数患者每日一次口服,用21天停7天,阿替利珠单抗800 mg静脉每2周一次,主要目标为安全性和耐受性。2013年12月27日至2016年5月9日入组152例患者,截至2017年9月4日150例接受至少一剂阿替利珠单抗,最常见全等级治疗相关不良事件为腹泻(67%)、皮疹(48%)和乏力(40%),发生1例(<1%)治疗相关5级不良事件(脓毒症)。
要点
- 阿替利珠单抗联合考比替尼在实体瘤患者中安全性可控,最常见不良事件为腹泻、皮疹和乏力。
- 客观缓解见于转移性结直肠癌7/84例(8%)、黑色素瘤9/22例(41%)和非小细胞肺癌5/28例(18%)。
- 临床活性与KRAS/BRAF状态无关,但转移性结直肠癌中潜在协同活性未在后续III期研究中证实。
核心结论
- 阿替利珠单抗联合考比替尼安全性可控且具有临床活性,与KRAS/BRAF状态无关;转移性结直肠癌中虽见潜在协同活性,但未在后续III期研究中证实。
研究设计与样本
- 这项I/Ib期研究在剂量递增阶段和多个适应症特异性剂量扩展队列中,治疗未接受过PD-L1/PD-1治疗的实体瘤患者。
- 多数患者考比替尼每日一次口服,用21天停7天;阿替利珠单抗800 mg静脉每2周一次。
- 主要目标为安全性和耐受性,次要终点包括客观缓解率、无进展生存期和总生存期。
- 2013年12月27日至2016年5月9日入组152例患者;截至2017年9月4日,150例接受至少一剂阿替利珠单抗,其中剂量递增队列14例、剂量扩展队列136例。
- 患者包括转移性结直肠癌84例、黑色素瘤22例、非小细胞肺癌28例和其他实体瘤16例。
主要发现
- 最常见全等级治疗相关不良事件为腹泻(67%)、皮疹(48%)和乏力(40%),与单药考比替尼和阿替利珠单抗相似。
- 发生1例(<1%)治疗相关5级不良事件(脓毒症)。
- 分别有45例(30%)和23例(15%)患者因不良事件停用考比替尼和阿替利珠单抗。
- 确认缓解见于转移性结直肠癌7/84例(8%,其中6例为微卫星低度/稳定,1例为微卫星不稳定)、黑色素瘤9/22例(41%)和非小细胞肺癌5/28例(18%)。
- 临床活性与KRAS/BRAF状态无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 转移性结直肠癌中观察到的潜在协同活性未在后续III期研究中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune checkpoint inhibition. We investigated the safety and clinical activity of combining a MEK inhibitor, cobimetinib, and a programmed cell death 1 ligand 1 (PD-L1) inhibitor, atezolizumab, in patients with solid tumors. PATIENTS AND METHODS: This phase I/Ib study treated PD-L1/PD-1-naive patients with solid tumors in a dose-escalation stage and then in multiple, indication-specific dose-expansion cohorts. In most patients, cobimetinib was dosed once daily orally for 21 days on, 7 days off. Atezolizumab was dosed at 800 mg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary end points included objective response rate, progression-free survival, and overall survival. RESULTS: Between 27 December 2013 and 9 May 2016, 152 patients were enrolled. As of 4 September 2017, 150 patients received ≥1 dose of atezolizumab, including 14 in the dose-escalation cohorts and 136 in the dose-expansion cohorts. Patients had metastatic colorectal cancer (mCRC; n = 84), melanoma (n = 22), non-small-cell lung cancer (NSCLC; n = 28), and other solid tumors (n = 16). The most common all-grade treatment-related adverse events (AEs) were diarrhea (67%), rash (48%), and fatigue (40%), similar to those with single-agent cobimetinib and atezolizumab. One (<1%) treatment-related grade 5 AE occurred (sepsis). Forty-five (30%) and 23 patients (15%) had AEs that led to discontinuation of cobimetinib and atezolizumab, respectively. Confirmed responses were observed in 7 of 84 patients (8%) with mCRC (6 responders were microsatellite low/stable, 1 was microsatellite instable), 9 of 22 patients (41%) with melanoma, and 5 of 28 patients (18%) with NSCLC. Clinical activity was independent of KRAS/BRAF status across diseases. CONCLUSIONS: Atezolizumab plus cobimetinib had manageable safety and clinical activity irrespective of KRAS/BRAF status. Although potential synergistic activity was seen in mCRC, this was not confirmed in a subsequent phase III study. CLINICALTRIALS.GOV IDENTIFIER: NCT01988896 (the investigators in the NCT01988896 study are listed in the supplementary Appendix, available at Annals of Oncology online).
引用
- Hellmann MD, Kim TW, Lee CB, et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol. 2019. PMID: 30918950. doi:10.1093/annonc/mdz113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。